Compass Financial Management’s Biogen BIIB Stock Holding History

Compass Financial Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216	Buy	+1	New	+$191	﹤0.01%	1478

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Compass Financial Management's BIIB Position: Q2 2026 in Review

Compass Financial Management opened a new position in Biogen (BIIB) in Q2 2026: 1 share worth $216. The stake represents ﹤0.01% of the portfolio and ranks #1478 among its holdings.

981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Compass Financial Management held 1 share of Biogen worth $216 as of Q2 2026.
Biogen was a new Compass Financial Management position in Q2 2026.
Biogen made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #1478 holding.
981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.